Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...
The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical ...
Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...
UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...
Experts are now calling for NHS guidance - which does not recommend managing diabetes with different drugs depending on age - ...
AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...
Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.
The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...
Certain diabetes medications may have additional health benefits for older adults, scientists from the University of Glasgow ...
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Tom Nolan reviews this week’s research “Small individual gain, larger population gain” sounds like the theme for a preventive medicine conference. It’s actually the headline of an editorial about a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback